Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ODC1 | P11926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971720 | 0.96 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL31749258 | 0.95 | MEN1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL26157632 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6953888 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL25865981 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL14389110 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6952808 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL20977729 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6947738 | 0.94 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11024894 | 0.90 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-1241164-B1 | PROCESS FOR PREPARATION OF TETRAHYDROPYRANYLOXYAMINES | MITSUBISHI RAYON CO (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040030160-A1 | Process for preparation of tetrahydropyranyoxyamines | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| EP-1241164-A1 | PROCESS FOR PREPARATION OF TETRAHYDROPYRANYLOXYAMINES | Mitsubishi Rayon Co., Ltd. (JP) | 2002-09-18 | — | — | EP | disclosed |
| EP-0009776-B1 | N-MONOHYDROXYPROPYLAMIDES, N-DIHYDROXYPROPYLAMIDES AND THEIR ACETONOIDES OF ALL-E AND 13-Z RETINOIC ACID, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-07-28 | — | — | EP | disclosed |
| EP-0009776-A1 | N-monohydroxypropylamides, N-dihydroxypropylamides and their acetonoides of all-E and 13-Z retinoic acid, process for their preparation and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-04-16 | — | — | EP | disclosed |
| US-4167632-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1979-09-11 | — | — | US | disclosed |
| US-4122265-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030160-A1 | Process for preparation of tetrahydropyranyoxyamines | PNMT, HRH4, HRH1 | MEN1 3101/4885KMT2A 1802/4885KDM4C 1847/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MEN1 1555/4885KMT2A 1202/4885KDM4C 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.